Author

Thomas H. Jozefiak

Observed name: THOMAS H. JOZEFIAK

ORCID: 0000-0001-8370-6102

Observed ORCID: 0000-0001-8370-6102

OpenAlex ID: A5061859828

First‐in‐human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations

2023 · Mark S. Fineman, Christine L. N. Bryant, et al. · Diabetes Obesity and Metabolism · 11

SuperGAG biopolymers for treatment of excessive bladder permeability

2021 · Rheal A. Towner, Beverley Greenwood‐Van Meerveld, et al. · Pharmacology Research & Perspectives · 9

Development of a targeted oral pharmacologic duodenal exclusion therapy for the treatment of metabolic diseases

2025 · Taylor L. Carlson, Kevin Colbert, et al. · Science Advances · 4

Development of a unique crosslinked glycosaminoglycan for soft tissue repair: Treatment of interstitial cystitis/bladder pain syndrome

2025 · Richard W. Heidebrecht, Thomas H. Jozefiak, et al. · PLoS ONE · 3

855-P: GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Reduces Glucose and Bodyweight in Patients with Type 2 Diabetes

2024 · MARK FINEMAN, KEVIN COLBERT, et al. · Diabetes · 1

823-P: GLY-200, a Pharmacologic Duodenal Exclusion Therapy, Improved Metabolic Parameters in the DIO Rat

2023 · ASHISH NIMGAONKAR, CHRISTINE BRYANT, et al. · Diabetes · 1

1209-P: Profound Metabolic Benefits Observed in an Eight-Week GK Rat Study of a Novel Orally Administered Polymeric Duodenal Exclusion Therapy: Implications for Type 2 Diabetes (T2D) Therapy

2021 · ASHISH NIMGAONKAR, STEVEN POLOMOSCANIK, et al. · Diabetes · 1

220-OR: First-in-Human Study of a Pharmacological Duodenal Exclusion Therapy Mimics a Roux-en-Y Gastric Bypass Biomarker Signature

2023 · MARK FINEMAN, CHRISTINE BRYANT, et al. · Diabetes

833-P: Duodenal Targeting by Oral Pharmacologic Duodenal Exclusion Therapy for Treatment of Type 2 Diabetes (T2D)

2023 · ASHISH NIMGAONKAR, CHRISTINE BRYANT, et al. · Diabetes

832-P: Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat

2023 · MARK FINEMAN, CHRISTINE BRYANT, et al. · Diabetes

Author response for "First‐in‐human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations"

2023 · Mark S. Fineman, Christine L. N. Bryant, et al. · Publons reviews and discussion

818-P: Chronic Oral Polymeric Duodenal Exclusion Therapy Has Profound Metabolic Benefits in a T2D Rat Model and Affects Duodenal Morphological Enteroplasticity Similar to RYGB surgery: Implications for T2D Therapy

2022 · ASHISH NIMGAONKAR, FLORENCE GUERINA, et al. · Diabetes

Works count: 12

Citation count: 30

H-index: 3

I10-index: 1